Co-Diagnostics, Inc. Common Stock
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provide… Read more
Co-Diagnostics, Inc. Common Stock (CODX) - Net Assets
Latest net assets as of September 2025: $39.83 Million USD
Based on the latest financial reports, Co-Diagnostics, Inc. Common Stock (CODX) has net assets worth $39.83 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($44.74 Million) and total liabilities ($4.91 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $39.83 Million |
| % of Total Assets | 89.02% |
| Annual Growth Rate | 81.66% |
| 5-Year Change | -18.57% |
| 10-Year Change | N/A |
| Growth Volatility | 1405.22 |
Co-Diagnostics, Inc. Common Stock - Net Assets Trend (2014–2024)
This chart illustrates how Co-Diagnostics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Co-Diagnostics, Inc. Common Stock (2014–2024)
The table below shows the annual net assets of Co-Diagnostics, Inc. Common Stock from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $54.31 Million | -36.86% |
| 2023-12-31 | $86.01 Million | -24.89% |
| 2022-12-31 | $114.52 Million | -14.84% |
| 2021-12-31 | $134.48 Million | +101.62% |
| 2020-12-31 | $66.70 Million | +3739.19% |
| 2019-12-31 | $1.74 Million | +264.08% |
| 2018-12-31 | $-1.06 Million | -127.50% |
| 2017-12-31 | $3.85 Million | +228.58% |
| 2016-12-31 | $-2.99 Million | -160.99% |
| 2015-12-31 | $-1.15 Million | -927.67% |
| 2014-12-31 | $138.63K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Co-Diagnostics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3154948300.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $37.90K | 0.07% |
| Other Comprehensive Income | $418.44K | 0.77% |
| Other Components | $86.90 Million | 160.00% |
| Total Equity | $54.31 Million | 100.00% |
Co-Diagnostics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Co-Diagnostics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
California First National Bancorp
OTCQX:CFNB
|
$4.44 Million |
|
Grey Cloak Tech Inc
OTCQB:HYEX
|
$4.44 Million |
|
DUG Foodtech AB (publ)
ST:VUXEN
|
$4.44 Million |
|
DRC Systems India Limited
NSE:DRCSYSTEMS
|
$4.44 Million |
|
Ravelin Properties REIT
TO:RPR-UN
|
$4.43 Million |
|
Glacier Media Inc
PINK:GLMFF
|
$4.43 Million |
|
MILIBOO. S.A. EO -10
F:7X2
|
$4.43 Million |
|
Toppoint Holdings Inc.
NYSE MKT:TOPP
|
$4.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Co-Diagnostics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 86,013,615 to 54,311,918, a change of -31,701,697 (-36.9%).
- Net loss of 37,639,008 reduced equity.
- New share issuances of 103,914 increased equity.
- Other comprehensive income increased equity by 271,742.
- Other factors increased equity by 5,561,655.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-37.64 Million | -69.3% |
| Share Issuances | $103.91K | +0.19% |
| Other Comprehensive Income | $271.74K | +0.5% |
| Other Changes | $5.56 Million | +10.24% |
| Total Change | $- | -36.86% |
Book Value vs Market Value Analysis
This analysis compares Co-Diagnostics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.04x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 4.33x to 0.04x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | $0.53 | $2.29 | x |
| 2015-12-31 | $-0.10 | $2.29 | x |
| 2016-12-31 | $-8.03 | $2.29 | x |
| 2017-12-31 | $10.54 | $2.29 | x |
| 2018-12-31 | $-2.54 | $2.29 | x |
| 2019-12-31 | $3.11 | $2.29 | x |
| 2020-12-31 | $71.46 | $2.29 | x |
| 2021-12-31 | $134.91 | $2.29 | x |
| 2022-12-31 | $109.14 | $2.29 | x |
| 2023-12-31 | $87.93 | $2.29 | x |
| 2024-12-31 | $53.71 | $2.29 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Co-Diagnostics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -69.30%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -961.37%
- • Asset Turnover: 0.06x
- • Equity Multiplier: 1.18x
- Recent ROE (-69.30%) is above the historical average (-120.48%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | -756.07% | 0.00% | 0.00x | 1.87x | $-1.06 Million |
| 2015 | 0.00% | -20431.68% | 0.03x | 0.00x | $-1.93 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.63 Million |
| 2017 | -180.73% | -90827.88% | 0.00x | 1.21x | $-7.34 Million |
| 2018 | 0.00% | -15714.27% | 0.03x | 0.00x | $-6.17 Million |
| 2019 | -356.63% | -2882.00% | 0.10x | 1.28x | $-6.37 Million |
| 2020 | 63.69% | 56.98% | 1.05x | 1.07x | $35.81 Million |
| 2021 | 27.26% | 37.45% | 0.61x | 1.19x | $23.21 Million |
| 2022 | -12.43% | -41.61% | 0.28x | 1.07x | $-25.69 Million |
| 2023 | -41.08% | -518.68% | 0.07x | 1.11x | $-43.93 Million |
| 2024 | -69.30% | -961.37% | 0.06x | 1.18x | $-43.07 Million |
Industry Comparison
This section compares Co-Diagnostics, Inc. Common Stock's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Co-Diagnostics, Inc. Common Stock (CODX) | $39.83 Million | -756.07% | 0.12x | $4.44 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |